Pemetrexed for advanced non-small cell lung cancer patients with interstitial lung disease

BACKGROUND: Non-small cell lung cancer (NSCLC) patients with interstitial lung disease (ILD) need to be approached carefully given the high incidence of pulmonary toxicity. Pemetrexed (PEM) is the key drug for the treatment of NSCLC. However, its safety, especially with respect to the exacerbation o...

Descripción completa

Detalles Bibliográficos
Autores principales: Kato, Motoyasu, Shukuya, Takehito, Takahashi, Fumiyuki, Mori, Keita, Suina, Kentaro, Asao, Tetsuhiko, Kanemaru, Ryota, Honma, Yuichiro, Muraki, Keiko, Sugano, Koji, Shibayama, Rina, Koyama, Ryo, Shimada, Naoko, Takahashi, Kazuhisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4107964/
https://www.ncbi.nlm.nih.gov/pubmed/25012241
http://dx.doi.org/10.1186/1471-2407-14-508

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4107964/
https://www.ncbi.nlm.nih.gov/pubmed/25012241
http://dx.doi.org/10.1186/1471-2407-14-508

Ejemplares similares